SynthesisBMC pregnancy and childbirth2026
Prescribing patterns for hypertensive disorders of pregnancy in low- and middle-income countries: a systematic review.
Synthesis in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertensive Disorders of Pregnancy (HDPs), encompassing gestational hypertension, pre-eclampsia, and eclampsia, affect approximately 18 million pregnancies globally. While international guidelines specify management for these disorders, their implementation in low-and middle-income countries (LMICs) is unassessed. Therefore, this systematic review aims to assess the prescribing patterns for HDPs to gauge suitable recommendations for practitioners in LMICs.
methodsA systematic review was conducted using PubMed, CINAHL, Scopus and Google Scholar using relevant terms for HDPs, prescribing patterns and LMICs. Observational studies published between January 2000 and November 2023 reporting management of HDPs in LMICs were included. The quality of the articles was screened using the National Heart Lung and Blood Institute (NHLBI) quality assessment tool.
resultsA total of 54 studies comprising 14,598 HDP cases from 17 LMICs were included. Of these studies, 18 reported prescriptions for gestational hypertension, in which, calcium channel blockers were reported to be prescribed in all, while the frequency of other prescribed medications included labetalol (89.0%) and methyldopa (66.7%). 41 studies reported medications for pre-eclampsia which included magnesium sulfate—MgSO4 (68.3%), nifedipine (61.0%), methyldopa (48.8%) and labetalol (43.9%) prescriptions. A majority of the 28 studies reporting on eclampsia mentioned the use of MgSO4, while 33% prescribed diazepam, and phenytoin was prescribed in 15% of the studies.
conclusionMajority of LMICs tend to prescribe the established first line medications for HDPs. Slight differences are seen in combinations, likely due to use of different guidelines and medication availability. Standardization of institutional guidelines and strategies to increase adherence to guidelines across LMICs are crucial for improved outcomes and safer prescribing patterns among physicians. Several studies report an absence of institutional guidelines, while practices differ from international guidelines, necessitating the need for standardization of prescribing patterns across resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.